文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

急诊科实施吸入依前列醇方案的回顾性审查

A retrospective review of implementation of an inhaled epoprostenol protocol in the emergency department.
PubMed 文献 · Am J Emerg Med · 2022-06-08
一句话结论急诊科按临床路径使用吸入依前列醇的15例回顾性病例中,未出现临床显著低血压(MAP<65),多数患者FiO2需求下降,最常见指征为肺栓塞。

该回顾性研究在三级医院一级创伤中心急诊科实施吸入依前列醇临床路径后,通过自动查询筛选出20例使用记录,最终15例符合纳入标准(排除院前启动、开医嘱未给药、给药不足1小时者)。主要观察指标为不良反应(如低血压)监测、FiO2需求随时间变化趋势及启动吸入依前列醇的临床指征。结果显示,急诊科使用吸入依前列醇的病例中无一例出现临床显著低血压(MAP<65),平均血管升压药需求随时间未增加,多数患者给药后FiO2需求下降;人工病历审查显示最常见启动指征为肺栓塞。作者认为需要进一步研究以制定急诊科使用吸入性肺血管扩张剂的临床方案。

要点

  • 急诊科按临床路径启动吸入依前列醇的15例中,无一例出现临床显著低血压(MAP<65),平均血管升压药需求随时间未增加。
  • 多数患者在使用吸入依前列醇后FiO2需求下降。
  • 人工病历审查显示,启动吸入依前列醇最常见的指征为肺栓塞。
  • 作者认为,需要进一步研究以制定急诊科使用吸入性肺血管扩张剂的临床方案。

适用人群与场景

  • 在三级医院一级创伤中心急诊科启动吸入依前列醇的患者;排除院前启动、开医嘱但未给药、给药时间不足1小时者。

诊断标准与关键阈值

  • 临床路径适用于顽固性低氧血症、右心室功能障碍和顽固性低氧血症(原文此处重复列出顽固性低氧血症)病例。
  • 排除标准:院前启动吸入依前列醇、开医嘱但未给药、给药时间不足1小时。

研究设计与关键结果

  • 回顾性审查:自动查询急诊科启动吸入依前列醇的病例共20例,最终15例符合纳入标准。
  • 在急诊科使用吸入依前列醇的病例中,无一例出现临床显著低血压(MAP<65),平均血管升压药需求随时间未增加。
  • 多数患者在使用吸入依前列醇后FiO2需求下降。
  • 人工病历审查显示,启动吸入依前列醇最常见的指征为肺栓塞。
  • 未发现可归因于给药的 hypotension 或其他不良反应(原文:there were no cases of hypotension or other adverse effects that appear to be attributable to medication administration)。

证据类型、等级与局限

  • 证据类型:回顾性审查。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在三级医院一级创伤中心急诊科实施吸入依前列醇临床路径后,按路径使用该药未出现临床显著低血压(MAP<65),平均血管升压药需求未增加;作者认为需要进一步研究以制定急诊科使用吸入性肺血管扩张剂的临床方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Inhaled epoprostenol is a selective pulmonary vasodilator that has shown a potentially broad number of applications in the management of critically ill patients. To date, the vast majority of the literature with regard to efficacy, indications for use, and adverse effects of inhaled epoprostenol is focused on use of this agent in critical care settings, with relatively little literature describing use of inhaled epoprostenol in the Emergency Department. This retrospective review sought to examine instances in which inhaled epoprostenol was administered in the Emergency Department of a tertiary-care, Level I trauma center following implementation of a clinical pathway for administration of this medication for cases of refractory hypoxemia, RV dysfunction, and refractory hypoxemia. Primary outcomes were monitoring for adverse effects (i.e. hypotension), trend in FiO2 requirement over time, and clinical indication for initiation of inhaled epoprostenol.

METHODS: An automated review was performed to query cases in which inhaled epoprostenol had been initiated in the Emergency Department following adoption of the inhaled epoprostenol clinical pathway. Cases were excluded if the medication was initiated in the prehospital setting, ordered but not administered, or administered for a period of <1 h. Vital signs and co-administration of vasopressors were followed before and following epoprostenol administration to assess for change over time. Clinical indication of epoprostenol administration was assessed via manual chart review.

RESULTS: Inhaled epoprostenol was administered in 20 instances, with 15 cases ultimately meeting inclusion criteria. There were no cases of clinically significant hypotension (MAP <65) in any of the cases in which inhaled epoprostenol was administered in the Emergency Department, and mean vasopressor requirement did not increase over time. A majority of patients saw a reduction in FiO2 requirement following administration of inhaled epoprostenol. The most common indication for initiation of inhaled epoprostenol based on manual chart review was pulmonary embolism.

DISCUSSION: In this review of cases in which inhaled epoprostenol was administered following adoption of a clinical pathway for medication administration, there were no cases of hypotension or other adverse effects that appear to be attributable to medication administration. Pulmonary embolism and refractory hypoxemia were the most common noted indications for administration of inhaled epoprostenol. Further research is warranted regarding development of clinical protocols for administration of inhaled pulmonary vasodilators in the Emergency Department setting.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Toomey D, O'Brien M, Hayes BD, et al. A retrospective review of implementation of an inhaled epoprostenol protocol in the emergency department. Am J Emerg Med. 2022. PMID: 35709539. doi:10.1016/j.ajem.2022.06.009

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。